Detailed Research on Ulcerative Colitis - Pipeline Review, H2 2016
Ulcerative Colitis - Pipeline Review, H2 2016 is a new market research publication announced by Reportstack. This report provides an overview of the Ulcerative Colitis (Gastrointestinal) pipeline landscape.
Ulcerative Colitis (Colitis ulcerosa or UC) is a chronic disease mainly of the large intestine or colon and a type of Inflammatory Bowel Disease (IBD). The disease is characterized by open sores and ulcers in the colon. The risk factors for UC include smoking, family history of the disease, liver disease, colon cancer, depression, and severe dehydration. Common symptoms of ulcerative colitis include rectal bleeding, abdominal pain, and diarrhea. Treatment options for ulcerative colitis include surgery (removal of colon) or drug therapy with aminoasylates (ASA), immunomodulators, and corticosteroids.
To access full report with TOC, please visit Ulcerative Colitis - Pipeline Review, H2 2016
Report Highlights
This report provides comprehensive information on the therapeutics under development for Ulcerative Colitis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Ulcerative Colitis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Ulcerative Colitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 6, 14, 28, 20, 1, 1, 45, 12 and 1 respectively for Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 10 and 1 molecules, respectively for Ulcerative Colitis.
Ulcerative Colitis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from a proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Ulcerative Colitis (Gastrointestinal).
- The pipeline guide reviews pipeline therapeutics for Ulcerative Colitis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Ulcerative Colitis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Ulcerative Colitis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Ulcerative Colitis (Gastrointestinal)
- The pipeline guide reviews pipeline therapeutics for Ulcerative Colitis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Ulcerative Colitis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Ulcerative Colitis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Ulcerative Colitis (Gastrointestinal)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Ulcerative Colitis (Gastrointestinal).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Ulcerative Colitis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
Companies Mentioned
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Ulcerative Colitis (Gastrointestinal).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Ulcerative Colitis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
Companies Mentioned
4D Pharma Plc AbbVie Inc Abivax S.A. Advinus Therapeutics Ltd Aerpio Therapeutics, Inc. Am-Pharma B.V. Amgen Inc. Aptevo Therapeutics Inc Arena Pharmaceuticals, Inc. Atlantic Healthcare Plc Bionovis SA Bristol-Myers Squibb Company Celgene Corporation Cellceutix Corporation ChemoCentryx, Inc. ChironWells GmbH Coherus BioSciences, Inc. Cosmo Pharmaceuticals NV Dr. Falk Pharma GmbH EA Pharma Co Ltd Eli Lilly and Company Enceladus Pharmaceuticals BV enGene, Inc Enterome Bioscience SA Epirus Biopharmaceuticals, Inc. Flexion Therapeutics, Inc. Galapagos NV Genentech, Inc. Genor BioPharma Co Ltd GlaxoSmithKline Plc GW Pharmaceuticals Plc iCo Therapeutics Inc. Idera Pharmaceuticals, Inc. InDex Pharmaceuticals AB Innovate Biopharmaceuticals, Inc. INOXIA Lifesciences GmbH Intas Pharmaceuticals Ltd. Johnson & Johnson Kaken Pharmaceutical Co., Ltd. Kyowa Hakko Kirin Co., Ltd. LIPID THERAPEUTICS GmbH Lycera Corp. Medestea Research & Production S.p.A. Merck & Co., Inc. Miyarisan Pharmaceutical Company, Ltd Momenta Pharmaceuticals, Inc. Morphotek, Inc. Mycenax Biotech Inc. NeuClone Pty Ltd Oncobiologics, Inc. OSE Immunotherapeutics Pfizer Inc. Pluristem Therapeutics Inc. ProtAb Ltd Protagonist Therapeutics Inc. Protalix BioTherapeutics, Inc. Qu Biologics Inc. Re-Pharm Limited Rebiotix Inc. Sandoz International GmbH Seres Therapeutics, Inc. Shire Plc Sigmoid Pharma Limited Stelic Institute & Co., Inc. Sterna biologicals Gmbh & Co KG Synergy Pharmaceuticals, Inc. Synlogic Inc Takeda Pharmaceutical Company Limited Therapeutic Proteins International, LLC Therapix Biosciences Ltd. Theravance Biopharma, Inc. Tillotts Pharma AG TopiVert Ltd Trino Therapeutics Limited UCB S.A. Ventria Bioscience
Contact:
Debora White
Manager - Marketing
Ph: +1-888-789-6604
Reportstack Market Research
###
posted by Reportstack @ 03:57
0 Comments
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home